← Back to patent-cliff list
CAS 106-95-6
3-bromoprop-1-ene1-Bromo-2-propene
Codes: MRIO-001, MRIO-002, Atorvastatin-157, METOPR-011, DOLU-016, LEVO-021, PRUC-025, IXAB-054, PACR-005, TREP-032, ERTA-002, EPTI-061
Application context (from source-drug indications)
Diabetic neuropathyMirogabalin besilatePostherpetic neuralgiaMirogabalin besilatePeripheral nervous system disorderMirogabalin besilateCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilAngina pectorisIvabradine Hydrochloride/Metoprolol TartrateHIV infectionDolutegravir SodiumLabour and deliveryDolutegravir SodiumMycobacterium tuberculosis infectionDolutegravir SodiumHepatitisDolutegravir SodiumHerpesvirus infectionDolutegravir SodiumHepatic function declineDolutegravir SodiumMajor depressive disorderLevomilnacipran HydrochlorideIschaemic strokeLevomilnacipran HydrochlorideDepressionLevomilnacipran HydrochlorideConstipationPrucalopride SuccinatePostoperative complicationPrucalopride SuccinateEnteral feeding intolerancePrucalopride SuccinateOpioid-induced constipationPrucalopride SuccinatePainPrucalopride SuccinateIntestinal pseudo-obstructionPrucalopride SuccinateHyperlipidaemiaAtorvastatin strontiumSubarachnoid haemorrhageAtorvastatin strontiumHypertensionAtorvastatin strontiumBreast cancerIxabepiloneMetastatic breast cancerIxabepiloneCervical cancerIxabepiloneProstate cancerIxabepiloneSolid tumourIxabepiloneNeutropeniaIxabepiloneHypertensionMetoprolol SuccinateAngina pectorisMetoprolol SuccinateHeart failureMetoprolol SuccinateHyperthyroidismMetoprolol SuccinateArrhythmiaMetoprolol SuccinateCardiac neurosisMetoprolol SuccinateMyelofibrosisPacritinib CitrateThrombocytopeniaPacritinib CitrateAcute myeloid leukaemiaPacritinib CitrateEssential thrombocythaemiaPacritinib CitratePolycythaemia veraPacritinib CitrateChronic myelomonocytic leukaemiaPacritinib CitrateInterstitial lung diseaseTreprostinilPulmonary hypertensionTreprostinilPulmonary arterial hypertensionTreprostinilIdiopathic pulmonary fibrosisTreprostinilPulmonary fibrosisTreprostinilIdiopathic pulmonary arterial hypertensionTreprostinilComplicated skin and skin structure infectionErtapenem SodiumIntra-abdominal infectionErtapenem SodiumBacteraemiaErtapenem SodiumUrinary tract infectionErtapenem SodiumCommunity-acquired pneumoniaErtapenem SodiumPyelonephritisErtapenem SodiumUnstable anginaEptifibatideMyocardial infarctionEptifibatideIschaemic strokeEptifibatideAcute coronary syndromeEptifibatideSickle cell diseaseEptifibatideST段抬高型心肌梗死Eptifibatide
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Mirogabalin besilate | Tier C — Watch / trade | 2030 |
| Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril | Tier C — Watch / trade | - |
| Ivabradine Hydrochloride/Metoprolol Tartrate | Tier C — Watch / trade | - |
| Dolutegravir Sodium | Tier B — Position early | - |
| Levomilnacipran Hydrochloride | Tier C — Watch / trade | - |
| Prucalopride Succinate | Tier C — Watch / trade | - |
| Atorvastatin strontium | Tier C — Watch / trade | - |
| Ixabepilone | Tier C — Watch / trade | - |
| Metoprolol Succinate | Tier C — Watch / trade | - |
| Pacritinib Citrate | Tier C — Watch / trade | - |
| Treprostinil | Tier B — Position early | - |
| Ertapenem Sodium | Tier C — Watch / trade | - |
| Eptifibatide | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-bromoprop-1-ene→3-bromoprop-1-ene→ethyl 4-ethyl-3-hydroxyhept-6-enoate→4-ethyl-3-hydroxyhept-6-enoic acid→tert-butyl 2-(dimethoxyphosphoryl)acetate→(E)-tert-butyl 2-(3-ethylbicyclo[3.2.0]hept-3-en-6-ylidene)acetate→tert-butyl 2-(3-ethyl-6-(nitromethyl)bicyclo[3.2.0]hept-3-en-6-yl)acetate→tert-butyl 2-((1R,5S,6S)-3-ethyl-6-(nitromethyl)bicyclo[3.2.0]hept-3-en-6-yl)acetate→tert-butyl 2-((1R,5S,6S)-6-(((tert-butoxycarbonyl)amino)methyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetate
1,1-Dimethylethyl cyanoacetate→1-Bromo-2-propene→tert-Butyl 3-oxohex-5-enoate→tert-Butyl (3R)-3-hydroxyhex-5-enoate→tert-Butyl [(4R,6S)-6-(bromomethyl)-2-oxo-1,3-dioxan-4-yl]acetate→[(4S,6R)-6-[2-(tert-Butoxy)-2-oxoethyl]-2,2-dimethyl-1,3-dioxan-4-yl]methyl acetate→(4R,6S)-6-Hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-dimethylethyl ester
3-hydroxy-2-methyl-4H-pyran-4-one→3-(benzyloxy)-2-methyl-4H-pyran-4-one→3-(benzyloxy)-2-methylpyridin-4(1H)-one→3-(benzyloxy)-5-bromo-2-methylpyridin-4-ol→methyl 5-(benzyloxy)-4-hydroxy-6-methylnicotinate→methyl 4-acetoxy-5-(benzyloxy)-6-methylnicotinate→4-acetoxy-3-(benzyloxy)-5-(methoxycarbonyl)-2-methylpyridine 1-oxide→methyl 4-acetoxy-6-(acetoxymethyl)-5-(benzyloxy)nicotinate→6-(acetoxymethyl)-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylic acid→(2,4-difluorophenyl)methanamine→5-(benzyloxy)-N-(2,4-difluorobenzyl)-6-(hydroxymethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide→5-(benzyloxy)-N-(2,4-difluorobenzyl)-6-formyl-4-oxo-1,4-dihydropyridine-3-carboxamide→3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→3-bromoprop-1-ene→methyl 1-allyl-3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyridine-2-carboxylate→(R)-3-aminobutan-1-ol→(4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid→1-(3-methoxypropyl)piperidin-4-amine→methyl 4-acetamido-2-hydroxybenzoate→methyl 4-acetamido-5-chloro-2,3-dihydrobenzofuran-7-carboxylate→3-bromoprop-1-ene→methyl 4-acetamido-2-(allyloxy)benzoate→methyl 4-acetamido-3-allyl-2-hydroxybenzoate→methyl 4-acetamido-2-hydroxy-3-(2-oxoethyl)benzoate→methyl 4-acetamido-2-hydroxy-3-(2-hydroxyethyl)benzoate→methyl 4-acetamido-2,3-dihydrobenzofuran-7-carboxylate
1,1-Dimethylethyl cyanoacetate→1-Bromo-2-propene→tert-Butyl 3-oxohex-5-enoate→tert-Butyl (3R)-3-hydroxyhex-5-enoate→tert-Butyl [(4R,6S)-6-(bromomethyl)-2-oxo-1,3-dioxan-4-yl]acetate→[(4S,6R)-6-[2-(tert-Butoxy)-2-oxoethyl]-2,2-dimethyl-1,3-dioxan-4-yl]methyl acetate→(4R,6S)-6-Hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-dimethylethyl ester
tert-butyl (S,E)-(2-methyl-1-(2-methylthiazol-4-yl)-5-oxopent-1-en-3-yl)carbamate→(S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-amine→(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)ethan-1-one compound with ethane (1:1)→3,3-dimethylhexane-2,4-dione→(S)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-3-hydroxy-4,4-dimethylheptane-1,5-dione compound with ethane (1:1)→(S)-3-((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4,4-dimethylheptane-1,5-dione compound with ethane (1:1)→(S)-2-methylpent-4-enal→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-7-hydroxy-4,4,6,8-tetramethylundec-10-ene-1,5-dione compound with ethane (1:1)→(3S,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4,4,6,8-tetramethylundec-10-ene-1,5-dione compound with ethane (1:1)→tert-butyl ((S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)carbamate→tert-butyl ((1E,3S,5Z,10S,11S,12R,15S)-11,15-bis((tert-butyldimethylsilyl)oxy)-17-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-2,6,10,12,14,14-hexamethyl-1-(2-methylthiazol-4-yl)-13,17-dioxoheptadeca-1,5-dien-3-yl)carbamate compound with ethane (1:1)→(3S,6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid→(3S,6R,7S,8S,12Z,15S,16E)-15-amino-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid→(4S,7R,8S,9S,16S,Z)-4,8-bis((tert-butyldimethylsilyl)oxy)-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→(E)-2-methyl-3-(2-methylthiazol-4-yl)acrylaldehyde→(R)-2-methylpropane-2-sulfinamide→(R)-2-methyl-N-((1E,2E)-2-methyl-3-(2-methylthiazol-4-yl)allylidene)propane-2-sulfinamide→3-bromoprop-1-ene→(R)-2-methyl-N-((S,E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl)propane-2-sulfinamide→(S,E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-amine→tert-butyl (S,E)-(2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl)carbamate→tert-butyl ((3S,E)-5,6-dihydroxy-2-methyl-1-(2-methylthiazol-4-yl)hex-1-en-3-yl)carbamate
2-hydroxy-5-nitrobenzaldehyde→1-bromo-2-chloroethane→2-(2-chloroethoxy)-5-nitrobenzaldehyde→(2-(2-chloroethoxy)-5-nitrophenyl)methanol→3-bromoprop-1-ene→2-((allyloxy)methyl)-1-(2-chloroethoxy)-4-nitrobenzene→3-((allyloxy)methyl)-4-(2-chloroethoxy)aniline→4-(3-((allyloxy)methyl)phenyl)-2-chloropyrimidine→PACR-009→pyrrolidine→2,4-dichloropyrimidine→(3-(hydroxymethyl)phenyl)boronic acid→(3-(2-chloropyrimidin-4-yl)phenyl)methanol
(3aS,9aS)-5-methoxy-1-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1,3,3a,4,9,9a-hexahydro-2H-cyclopenta[b]naphthalen-2-one→(1R,2R,3aS,9aS)-1-((S)-3-hydroxyoctyl)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-2-ol→(1R,2R,3aS,9aS)-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-2,5-diol→2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetonitrile→(3-methoxyphenyl)methanol→tert-butyl((3-methoxybenzyl)oxy)dimethylsilane→3-bromoprop-1-ene→((2-allyl-3-methoxybenzyl)oxy)(tert-butyl)dimethylsilane→(2-allyl-3-methoxyphenyl)methanol→2-allyl-3-methoxybenzaldehyde→2-(((S)-dec-1-yn-5-yl)oxy)tetrahydro-2H-pyran→(6S)-1-(2-allyl-3-methoxyphenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)undec-2-yn-1-ol→(6S)-1-(2-allyl-3-methoxyphenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)undec-2-yn-1-one→(R)-diphenyl(pyrrolidin-2-yl)methanol→(1S,6S)-1-(2-allyl-3-methoxyphenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)undec-2-yn-1-ol→(((1S,6S)-1-(2-allyl-3-methoxyphenyl)-6-((tetrahydro-2H-pyran-2-yl)oxy)undec-2-yn-1-yl)oxy)(tert-butyl)dimethylsilane→(4R,9aS)-4-((tert-butyldimethylsilyl)oxy)-8-methoxy-3-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-1,4,9,9a-tetrahydro-2H-cyclopenta[b]naphthalen-2-one→(1R,2R,3aS,9aS)-5-methoxy-1-((3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)octyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-2-ol
methyl 2-bromoacetate→(1R,2R,3aS,9aS)-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalene-2,5-diol→(3-methoxyphenyl)methanol→tert-butyl((3-methoxybenzyl)oxy)dimethylsilane→3-bromoprop-1-ene→((2-allyl-3-methoxybenzyl)oxy)(tert-butyl)dimethylsilane→(2-allyl-3-methoxyphenyl)methanol→2-allyl-3-methoxybenzaldehyde→(R)-5-(but-3-yn-1-yl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane→(6R)-1-(2-allyl-3-methoxyphenyl)-6,7-bis((tert-butyldimethylsilyl)oxy)hept-2-yn-1-ol→(R)-1-(2-allyl-3-methoxyphenyl)-6,7-bis((tert-butyldimethylsilyl)oxy)hept-2-yn-1-one→(R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole→(1S,6R)-1-(2-allyl-3-methoxyphenyl)-6,7-bis((tert-butyldimethylsilyl)oxy)hept-2-yn-1-ol→(5S,10R)-5-(2-allyl-3-methoxyphenyl)-10-((tert-butyldimethylsilyl)oxy)-2,2,3,3,13,13,14,14-octamethyl-4,12-dioxa-3,13-disilapentadec-6-yne→(4R,9aS)-3-((R)-3,4-bis((tert-butyldimethylsilyl)oxy)butyl)-4-((tert-butyldimethylsilyl)oxy)-8-methoxy-1,4,9,9a-tetrahydro-2H-cyclopenta[b]naphthalen-2-one→(3aS,9aS)-1-((R)-3,4-bis((tert-butyldimethylsilyl)oxy)butyl)-5-methoxy-1,3,3a,4,9,9a-hexahydro-2H-cyclopenta[b]naphthalen-2-one→(1R,2R,3aS,9aS)-1-((R)-3,4-bis((tert-butyldimethylsilyl)oxy)butyl)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-2-ol→(R)-5-(2-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)ethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane→(R)-4-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)butane-1,2-diol→TREP-055→tert-butyl(((1R,2R,3aS,9aS)-5-methoxy-1-(2-((R)-oxiran-2-yl)ethyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-2-yl)oxy)diphenylsilane→(S)-1-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)octan-3-ol→(1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-ol→ethyl 2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetate→(S)-oxiran-2-ylmethanol→(R)-tert-butyldimethyl(oxiran-2-ylmethoxy)silane→trimethyl(prop-1-yn-1-yl)silane→(R)-1-((tert-butyldimethylsilyl)oxy)-6-(trimethylsilyl)hex-5-yn-2-ol→(R)-1-((tert-butyldimethylsilyl)oxy)hex-5-yn-2-ol
3-nitrobenzoic acid→3-bromoprop-1-ene→allyl 3-nitrobenzoate→allyl 3-aminobenzoate→(2S,4S)-4-(acetylthio)-1-((allyloxy)carbonyl)pyrrolidine-2-carboxylic acid→allyl (2S,4S)-4-(acetylthio)-2-((3-((allyloxy)carbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate→allyl (2S,4S)-2-((3-((allyloxy)carbonyl)phenyl)carbamoyl)-4-mercaptopyrrolidine-1-carboxylate→allyl (4R,5R,6S)-3-((diphenoxyphosphoryl)oxy)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate→allyl (4R,5S,6S)-3-(((3S,5S)-1-((allyloxy)carbonyl)-5-((3-((allyloxy)carbonyl)phenyl)carbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate→2,2-dimethyl-1,3-dioxane-4,6-dione→allyl (R)-2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate→allyl (4R,5R,6S)-6-((R)-1-hydroxyethyl)-4-methyl-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate→diphenyl phosphorochloridate
N-(((9H-fluoren-9-yl)methoxy)carbonyl)-S-trityl-L-cysteine→(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanoic acid→3-(tritylthio)propanoic acid→(S)-pyrrolidine-2-carboxylic acid→(S)-tert-butyl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(((S)-1-((S)-2-(((R)-1-amino-1-oxo-3-(tritylthio)propan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-4-oxobutanoate→L-cysteine hydrochloride→(R)-(9H-fluoren-9-yl)methyl (1-amino-1-oxo-3-(tritylthio)propan-2-yl)carbamate→(2R,3R)-2,3-dihydroxysuccinic acid→(R)-2-amino-3-(tritylthio)propanamide (2R,3R)-2,3-dihydroxysuccinate→(R)-1-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanamido)-3-(1H-indol-3-yl)propanoyl)pyrrolidine-2-carboxylic acid→EPTI-057→EPTI-058→(S)-2-amino-3-(1H-indol-3-yl)propanoic acid→(S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoic acid→3-bromoprop-1-ene→(R)-2-allyl 1-tert-butyl pyrrolidine-1,2-dicarboxylate→(R)-allyl 1-((S)-2-((tert-butoxycarbonyl)amino)-3-(1H-indol-3-yl)propanoyl)pyrrolidine-2-carboxylate→(R)-allyl 1-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(tert-butoxy)-4-oxobutanamido)-3-(1H-indol-3-yl)propanoyl)pyrrolidine-2-carboxylate→EPTI-065→EPTI-066→EPTI-067
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | (1R,5S)-3-ethyl-Bicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 3-ethylbicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]indene-2,5-diol Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 1-broMo-5-fluoro-2-Methyl-3-nitrobenzene Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | methyl 4-cyclopropyl-2-fluorobenzoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | tert-butyl 2-(4-amino-6-chloropyrimidin-5-yloxy)ethylmethylcarbamate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 2H-Benz[f]inden-2-one, 9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3,3a,4,9-tetrahydro-5-methoxy-1-[(3S)-3-[(tetrahydro-2H-pyran-2-yl)oxy]octyl]-, (3aS,9R)- Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-allyl-3-methoxybenzaldehyde Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (5S)-1-Decyn-5-ol Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.